Ptc Therapeutics annual operating margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ptc Therapeutics's operating margin was 50.09% for fiscal 2025.
View full Ptc Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 50.09% | +87.60 pp |
| 2024 | 2024-12-31 | −37.50% | +9.36 pp |
| 2023 | 2023-12-31 | −46.86% | +17.16 pp |
| 2022 | 2022-12-31 | −64.03% | +5.50 pp |
| 2021 | 2021-12-31 | −69.52% | +43.87 pp |
| 2020 | 2020-12-31 | −113.39% | −34.84 pp |
| 2019 | 2019-12-31 | −78.56% | −34.86 pp |
| 2018 | 2018-12-31 | −43.70% | −10.63 pp |
| 2017 | 2017-12-31 | −33.07% | +126.60 pp |
| 2016 | 2016-12-31 | −159.67% | +294.90 pp |
| 2015 | 2015-12-31 | −454.58% | −60.78 pp |
| 2014 | 2014-12-31 | −393.79% | −262.95 pp |
| 2013 | 2013-12-31 | −130.85% | −51.87 pp |
| 2012 | 2012-12-31 | −78.97% | −107.98 pp |
| 2011 | 2011-12-31 | 29.01% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 41.32% | +60.87 pp |
| Q1 2026 | 2026-03-31 | 16.50% | −66.00 pp |
| Q4 2025 | 2025-12-31 | −43.33% | +32.85 pp |
| Q3 2025 | 2025-09-30 | 1.43% | +29.13 pp |
| Q2 2025 | 2025-06-30 | −19.54% | +2.00 pp |
| Q1 2025 | 2025-03-31 | 82.50% | +104.13 pp |
| Q4 2024 | 2024-12-31 | −76.18% | −78.07 pp |
| Q3 2024 | 2024-09-30 | −27.70% | +32.41 pp |
| Q2 2024 | 2024-06-30 | −21.54% | +76.46 pp |
| Q1 2024 | 2024-03-31 | −21.63% | +31.74 pp |
| Q4 2023 | 2023-12-31 | 1.90% | +121.56 pp |
| Q3 2023 | 2023-09-30 | −60.11% | −28.71 pp |
| Q2 2023 | 2023-06-30 | −98.01% | −42.21 pp |
| Q1 2023 | 2023-03-31 | −53.37% | +4.80 pp |
| Q4 2022 | 2022-12-31 | −119.67% | −68.39 pp |
| Q3 2022 | 2022-09-30 | −31.40% | +35.68 pp |
| Q2 2022 | 2022-06-30 | −55.80% | +28.62 pp |
| Q1 2022 | 2022-03-31 | −58.17% | +25.05 pp |
| Q4 2021 | 2021-12-31 | −51.28% | +29.80 pp |
| Q3 2021 | 2021-09-30 | −67.09% | −20.52 pp |
| Q2 2021 | 2021-06-30 | −84.42% | +164.49 pp |
| Q1 2021 | 2021-03-31 | −83.22% | +53.02 pp |
| Q4 2020 | 2020-12-31 | −81.08% | −5.62 pp |
| Q3 2020 | 2020-09-30 | −46.56% | +38.12 pp |
| Q2 2020 | 2020-06-30 | −248.90% | −203.58 pp |
| Q1 2020 | 2020-03-31 | −136.23% | −7.20 pp |
| Q4 2019 | 2019-12-31 | −75.46% | −23.18 pp |
| Q3 2019 | 2019-09-30 | −84.68% | +5.32 pp |
| Q2 2019 | 2019-06-30 | −45.32% | −37.21 pp |
| Q1 2019 | 2019-03-31 | −129.03% | −99.17 pp |
| Q4 2018 | 2018-12-31 | −52.28% | −59.27 pp |
| Q3 2018 | 2018-09-30 | −90.00% | −16.19 pp |
| Q2 2018 | 2018-06-30 | −8.11% | +17.95 pp |
| Q1 2018 | 2018-03-31 | −29.87% | +69.41 pp |
| Q4 2017 | 2017-12-31 | 6.99% | +106.20 pp |
| Q3 2017 | 2017-09-30 | −73.81% | +65.68 pp |
| Q2 2017 | 2017-06-30 | −26.06% | +207.81 pp |
| Q1 2017 | 2017-03-31 | −99.28% | +104.17 pp |
| Q4 2016 | 2016-12-31 | −99.21% | +279.31 pp |
| Q3 2016 | 2016-09-30 | −139.49% | +292.50 pp |
| Q2 2016 | 2016-06-30 | −233.86% | +336.35 pp |
| Q1 2016 | 2016-03-31 | −203.45% | +305.38 pp |
| Q4 2015 | 2015-12-31 | −378.52% | −123.87 pp |
| Q3 2015 | 2015-09-30 | −432.00% | +1197.34 pp |
| Q2 2015 | 2015-06-30 | −570.21% | +942.55 pp |
| Q1 2015 | 2015-03-31 | −508.83% | −354.64 pp |
| Q4 2014 | 2014-12-31 | −254.65% | +155.53 pp |
| Q3 2014 | 2014-09-30 | −1,629.34% | −1603.09 pp |
| Q2 2014 | 2014-06-30 | −1,512.76% | −1301.89 pp |
| Q1 2014 | 2014-03-31 | −154.19% | −34.11 pp |
| Q4 2013 | 2013-12-31 | −410.18% | −312.12 pp |
| Q3 2013 | 2013-09-30 | −26.25% | +72.60 pp |
| Q2 2013 | 2013-06-30 | −210.87% | — |
| Q1 2013 | 2013-03-31 | −120.08% | — |
| Q3 2012 | 2012-09-30 | −98.06% | — |
| Q2 2012 | 2012-06-30 | −98.85% | — |
Over the last five reported fiscal years, Ptc Therapeutics's operating margin increased from −113.39% to 50.09%, a change of +163.49 percentage points. The latest reported quarter, Q2 2026, shows 41.32%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ptc Therapeutics filings at SEC.gov ↗